| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
MTOA-TFSI does not have a defined biological target as a therapeutic agent. It is an ionic liquid used as an electrolyte in electrochemical applications and as a research reagent. The compound is not intended to exert pharmacological effects. Its utility lies in its physical and chemical properties as an ionic liquid, including its high ionic conductivity, low volatility, and high thermal stability.
|
|---|---|
| ln Vitro |
Specific in vitro activity data for MTOA-TFSI as a pharmacological agent are not documented in the literature, as it is primarily used as an ionic liquid and research reagent. The compound is not characterized for direct biological activities such as enzyme inhibition, receptor modulation, or antimicrobial effects. Its effects in biological systems, if any, would be related to its potential toxicity as an ionic liquid.
|
| ln Vivo |
MTOA-TFSI is not used for in vivo pharmacological activity assessment as a drug compound. Its primary applications are as an electrolyte in electrochemical applications and as a research reagent. The compound is not intended to be administered to animals for pharmacological or toxicological studies. Its use is limited to research and industrial applications.
|
| Enzyme Assay |
MTOA-TFSI is not used in enzyme/receptor binding assays as a test compound. Its primary applications are as an electrolyte in electrochemical studies and as a research reagent. When used in research, it may be employed in studies of ionic liquid properties or in electrochemical applications. Standard chemical and electrochemical protocols are employed for its use, rather than biochemical assay procedures.
|
| Cell Assay |
MTOA-TFSI is not used in cell-based assays as a test compound. Its primary applications are as an ionic liquid and research reagent. The compound is not characterized for direct cellular effects, cytotoxicity, or any pharmacological activity. Its potential toxicity is a concern in laboratory settings, but it is not evaluated for pharmacological effects.
|
| Animal Protocol |
MTOA-TFSI is not used in animal studies as a pharmacological agent. Its primary applications are as an electrolyte in electrochemical applications and as a research reagent. The compound is not intended to be administered to animals for efficacy evaluations. Its use is limited to research and industrial applications.
|
| ADME/Pharmacokinetics |
MTOA-TFSI has a molecular weight of 648.85 g/mol and a molecular formula of C₂₇H₅₄F₆N₂O₄S₂. It is a colorless to pale yellow viscous liquid. The compound is used as an electrolyte in batteries, supercapacitors, and electrodeposition. It is typically stored under standard laboratory conditions, protected from moisture and light.
|
| Toxicity/Toxicokinetics |
MTOA-TFSI is intended for research use only and is not approved for human therapeutic applications. As an ionic liquid, comprehensive toxicological data are not extensively documented in the publicly accessible literature. Standard safety precautions should be observed when handling this compound, including the use of appropriate personal protective equipment. The compound should be handled in well-ventilated areas with proper waste disposal procedures.
|
| References | |
| Additional Infomation |
MTOA-TFSI (Methyltri-n-octylammonium bis(trifluoromethylsulfonyl)imide) (CAS#: 375395-33-8) is an ionic liquid used as an electrolyte in electrochemical applications and as a research reagent. This compound is not a drug and has not undergone clinical trials.
|
| Molecular Formula |
C27H54F6N2O4S2
|
|---|---|
| Molecular Weight |
648.85
|
| Exact Mass |
648.342
|
| CAS # |
375395-33-8
|
| PubChem CID |
16211009
|
| Appearance |
Colorless to light yellow viscous liquid
|
| Density |
1.11
|
| Melting Point |
<0℃
|
| Flash Point |
>110ºC
|
| Index of Refraction |
n20/D 1.439
|
| LogP |
11.735
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
23
|
| Heavy Atom Count |
41
|
| Complexity |
594
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C(F)(F)F)([N-]S(C(F)(F)F)(=O)=O)(=O)=O.[N+](C([H])([H])[H])(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H]
|
| InChi Key |
LAGQNGWYNLUQRI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C25H54N.C2F6NO4S2/c1-5-8-11-14-17-20-23-26(4,24-21-18-15-12-9-6-2)25-22-19-16-13-10-7-3;3-1(4,5)14(10,11)9-15(12,13)2(6,7)8/h5-25H2,1-4H3;/q+1;-1
|
| Chemical Name |
bis(trifluoromethylsulfonyl)azanide;methyl(trioctyl)azanium
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5412 mL | 7.7059 mL | 15.4119 mL | |
| 5 mM | 0.3082 mL | 1.5412 mL | 3.0824 mL | |
| 10 mM | 0.1541 mL | 0.7706 mL | 1.5412 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
